Activating the bile acid receptor TGR5 was found to reduce the number of immune cells that secrete proinflammatory proteins, suggesting that this receptor may be a therapeutic target for people with myasthenia gravis (MG), a study reported. The study, “…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like the option of continuing its use in future appointments, a series of surveys found. The surveys were conducted by the National Organization for Rare Disorders (NORD) and involved more than 800…
The first published case of a person developing ocular myasthenia gravis (MG) secondary to COVID-19 was described in a new report. The patient, a 65-year-old woman with a medical history of kidney cancer, pituitary tumor, and a blockage in the pulmonary artery in the lungs, ultimately was successfully…
The first participant has been dosed in a Phase 1/2a trial evaluating NMD670, NMD Pharma‘s investigational therapy for myasthenia gravis (MG). “I am pleased to announce that our lead program has entered the clinic. NMD670 has already shown great promise in preclinical studies and…
Treatment with Argenx‘s investigational therapy efgartigimod leads to significant and early reductions in the severity of generalized myasthenia gravis (gMG), regardless of the presence of antibodies against acetylcholine receptor (AChR), according to results from a Phase 3 clinical trial. Trial findings were presented earlier this month at…
Same But Different, a nonprofit U.K. group that uses art for social change, is inviting people to choose their favorite photographs in a calendar contest to heighten awareness of rare diseases, including amyotrophic lateral sclerosis (ALS). The organization’s panel of judges has pared the number of contest submissions to…
Tasks involving memory can be difficult for people with myasthenia gravis (MG) due to depression and the use of glucocorticosteroids, a study from Brazil found. The study, “Cognitive performance in patients with Myasthenia Gravis: an association with glucocorticosteroid use and depression,” was published in the…
A Phase 2 clinical trial of Harbour BioMed‘s investigational therapy batoclimab, also known as HBM9161, for myasthenia gravis (MG), has started dosing patients, the company said in a press release. The trial (NCT04346888) — being conducted at the Huashan Hospital in Shanghai, China — is…
For the first time, a real-world study comparing the effects of long-term intravenous (IVIG) and subcutaneous immunoglobulin (SCIG) maintenance therapy in adults with generalized myasthenia gravis (gMG) showed reduced impairments, less use of other medications, and improved…
A large-scale analysis of people with myasthenia gravis (MG) in North America revealed a higher prevalence of MG and other autoimmune disorders among their families, suggesting there may be a genetic component to the neuromuscular condition, a study reported. The…
Get regular updates to your inbox.
